Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Amsacrine
Drug ID BADD_D00137
Description Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.
Indications and Usage For treatment of acute myeloid leukaemia.
Marketing Status approved; investigational
ATC Code L01XX01
DrugBank ID DB00276
KEGG ID D02321
MeSH ID D000677
PubChem ID 2179
TTD Drug ID D0G9YH
NDC Product Code Not Available
UNII 00DPD30SOY
Synonyms Amsacrine | Cain's Acridine | Cain Acridine | Cains Acridine | meta-AMSA | meta AMSA | AMSA | m-AMSA | Amsidyl | SN-11841 | SN 11841 | SN11841 | NSC-156303 | NSC 156303 | NSC156303 | NSC-249992 | NSC 249992 | NSC249992 | Amsidine | Amsacrina | AMSA P-D | AMSA P D | AMSA PD | NSC-141549 | NSC 141549 | NSC141549
Chemical Information
Molecular Formula C21H19N3O3S
CAS Registry Number 51264-14-3
SMILES COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Proteinuria20.02.01.011--
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Rash23.03.13.001---
Renal failure20.01.03.005---
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sinus tachycardia02.03.03.010--
Skin disorder23.03.03.007---
Stomatitis07.05.06.005--
Tachycardia02.03.02.007---
Thrombocytopenia01.08.01.002---
Ureteric obstruction20.06.01.005---
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urticaria10.01.06.001; 23.04.02.001--
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.008--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Ejection fraction decreased13.14.02.003--
Lymphatic disorder01.09.01.003---
Perirectal abscess07.19.04.001; 11.01.07.005---
Protein urine present13.13.02.006---
Affect lability19.04.01.001---
Haemorrhage24.07.01.002---
Angiopathy24.03.02.007---
Blood alkaline phosphatase increased13.04.02.004--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages